Dasatinib
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dasatinib is an inhibitor of multiple tyrosine kinases with mechanism of action linked to a broad targeting of Src kinases, and is currently indicated for use as a second line chemotherapeutic agent for treatment of chronic myeloid leukemia resistant to another tyrosine kinase inhibitor, imatinib.15,16”
Citations
Cites
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationSawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Self-citationLombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Cited by
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
La Thangue, N. B., & Kerr, D. J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.121 · Cited by 332
Nambiar, A., Kellogg, D., Justice, J., Goros, M., Gelfond, J., Pascual, R., Hashmi, S., Masternak, M., Prata, L., LeBrasseur, N., et al. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104481 · Cited by 298
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Trial watch: Dendritic cell-based interventions for cancer therapy
Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies
Li, W., Croce, K., Steensma, D. P., McDermott, D. F., Ben-Yehuda, O., & Moslehi, J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.025 · Cited by 201
Gonzales, M. M., Garbarino, V. R., Marques Zilli, E., Petersen, R. C., Kirkland, J. L., Tchkonia, T., Musi, N., Seshadri, S., Craft, S., & Orr, M. E. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.62 · Cited by 203
Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-105627 · Cited by 187
Carayol, N., Vakana, E., Sassano, A., Kaur, S., Goussetis, D. J., Glaser, H., Druker, B. J., Donato, N. J., Altman, J. K., Barr, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005114107 · Cited by 180
Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer
Hantschel, O. D. (2012) · Genes & Cancer · doi:10.1177/1947601912458584 · Cited by 180
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
Raschi, E., Vasina, V., Ursino, M. G., Boriani, G., Martoni, A., & De Ponti, F. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.002 · Cited by 150
Gocho, Y., Liu, J., Hu, J., Yang, W., Dharia, N. V., Zhang, J., Shi, H., Du, G., John, A., Lin, T.-N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00167-4 · Cited by 153
Self-citationGuo, T., Agaram, N. P., Wong, G. C., Hom, G., D’Adamo, D. R., Maki, R. G., Schwartz, G. K., Veach, D. R., Clarkson, B. D., Singer, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0484 · Cited by 145
c-Src protein kinase inhibitors block assembly and maturation of dengue virus
Chu, J. J. H., & Yang, P. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611681104 · Cited by 140
A phosphotyrosine switch regulates organic cation transporters
Sprowl, J. A., Ong, S. S., Gibson, A. A., Hu, S., Du, G., Lin, W., Li, L., Bharill, S., Ness, R. A., Stecuła, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms10880 · Cited by 140
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis
Skhirtladze, C., Distler, O., Dees, C., Akhmetshina, A., Busch, N., Venalis, P., Zwerina, J., Spriewald, B., Pileckyte, M., Schett, G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23436 · Cited by 120
Polypharmacology in Precision Oncology: Current Applications and Future Prospects
Antolín, A. A., Workman, P., Mestres, J., & Al‐Lazikani, B. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160923115828 · Cited by 111
Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib
Levêque, D., Becker, G., Bilger, K., & Natarajan-Amé, S. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00872-4 · Cited by 90
VEGFR2 and Src Kinase Inhibitors Suppress Andes Virus-Induced Endothelial Cell Permeability
Gorbunova, E. E., Gavrilovskaya, I. N., Pepini, T., & Mackow, E. R. (2010) · Journal of Virology · doi:10.1128/jvi.02319-10 · Cited by 86
Gandin, V., Ferrarese, A., Via, M. D., Marzano, C., Chilin, A., & Marzaro, G. (2015) · Scientific Reports · doi:10.1038/srep16750 · Cited by 81
Bettenworth, D., & Rieder, F. (2014) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-7-5 · Cited by 85
The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis
Asano, Y., Bujor, A. M., & Trojanowska, M. (2010) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2010.06.008 · Cited by 85
Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps
He, D., Wu, Q., Tian, P., Liu, Y., Jia, Z., Li, Z., Wang, Y., Jin, Y., Luo, W., Li, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.007 · Cited by 80
Distler, J. H. W., & Distler, O. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.120196 · Cited by 73
Carayol, N., Katsoulidis, E., Sassano, A., Altman, J. K., Druker, B. J., & Platanias, L. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707934200 · Cited by 77
SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction
Guo, Y., Hu, H., Chen, W., Yin, H., Wu, J., Hsieh, C., He, Q., & Cao, J. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae015 · Cited by 73
Wu, Y. (2012) · Progress in heterocyclic chemistry · doi:10.1016/b978-0-08-096807-0.00001-4 · Cited by 69
Cellular Senescence in Idiopathic Pulmonary Fibrosis
Kellogg, D. L., Kellogg, D. L., Musi, N., & Nambiar, A. M. (2021) · Current Molecular Biology Reports · doi:10.1007/s40610-021-00145-4 · Cited by 67
Li, Y., Wang, P., Li, X. X., Yu, C. Y., Yang, H. J., Zhou, J., Xue, W., Tan, J., & Zhu, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165737 · Cited by 64
Creative approaches using proximity labeling to gain new biological insights
Milione, R. R., Schell, B.-B., Douglas, C. J., & Seath, C. P. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.12.005 · Cited by 57
Targeting angiogenesis in ovarian cancer
Schmitt, J., & Matei, D. E. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.004 · Cited by 57
Keersmaecker, K. D., Versele, M., Cools, J., Superti‐Furga, G., & Hantschel, O. D. (2008) · Leukemia · doi:10.1038/leu.2008.242 · Cited by 51
SRC Kinase in Glioblastoma: News from an Old Acquaintance
Cirotti, C., Contadini, C., & Barilà, D. (2020) · Cancers · doi:10.3390/cancers12061558 · Cited by 54
Iwasaki, K., Abarca, C., & Aguayo‐Mazzucato, C. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0416 · Cited by 51
Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review
Molaei, P., Mahaki, H., Manoochehri, H., & Tanzadehpanah, H. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666220426124834 · Cited by 49
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications
Vakana, E., & Platanias, L. C. (2011) · Oncotarget · doi:10.18632/oncotarget.413 · Cited by 50
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.161 · Cited by 46
Self-citationKalxdorf, M., Gade, S., Eberl, H. C., & Bantscheff, M. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.063859 · Cited by 46
Kumar, V., Singh, P., Gupta, S. K., Ali, V., & Verma, M. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04376-6 · Cited by 46
Targeted therapy in chronic myeloid leukemia
Jabbour, E. J., Cortes, J. E., Ghanem, H., O'Brien, S. M., & Kantarjian, H. M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.1.99 · Cited by 43
Self-citationMultilayered Polymer-Coated Carbon Nanotubes To Deliver Dasatinib
Moore, T. L., Grimes, S. W., Lewis, R. L., & Alexis, F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400448w · Cited by 41
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Petrazzuolo, A., Maiuri, M. C., Zitvogel, L., Kroemer, G., & Kepp, O. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2077898 · Cited by 41
Xie, N., Zhong, L., Liu, L., Fang, Y., Qi, X., Cao, J., Yang, B., He, Q., & Ying, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.02.019 · Cited by 40
Molecular Dissection of AKT Activation in Lung Cancer Cell Lines
Guo, Y., Du, J., & Kwiatkowski, D. J. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0558 · Cited by 41
da Silva, A., Magalhães, R. F., Branco, V., Silva, J., Cruz, F. F., Marques, P., Ferreira, T., Morales, M., Martins, M. A., Olsen, P. C., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13430 · Cited by 36
Dargart, J. L., Fish, K., Gordon, L. I., Longnecker, R., & Çen, O. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.05.003 · Cited by 37
El‐Wakil, M. H., El-Yazbi, A. F., Ashour, H. M. A., Khalil, M. A., Ismail, K. A., & Labouta, I. M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103089 · Cited by 35
Ma, B., Feng, H., Feng, C., Liu, Y., Zhang, H., Wang, J., Wang, W., He, P., & Niu, F. (2022) · Advanced Science · doi:10.1002/advs.202104850 · Cited by 36
Szabó, H., Fiorino, G., Spinelli, A., Rovida, S., Repici, A., Malesci, A., & Danese, S. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04171.x · Cited by 35
Yin, Y., Yuan, X., Gao, H., & Yang, Q. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118785 · Cited by 35
The human organic cation transporter OCT1 and its role as a target for drug responses
Brosseau, N., & Ramotar, D. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1670204 · Cited by 34
Targeted therapy of chronic myeloid leukemia
Sullivan, C., Peng, C., Chen, Y., Li, D., & Li, S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.001 · Cited by 33
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway
Abdalla, M., Thompson, L., Gurley, E., Burke, S. M., Ujjin, J., Newsome, R., & Somanath, P. R. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.008 · Cited by 36
Direct-acting and host-targeting HCV inhibitors: current and future directions
Chatel‐Chaix, L., Germain, M.-A., Götte, M., & Lamarre, D. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.08.002 · Cited by 37
Halpin-Veszeleiova, K., Mallouh, M. P., Williamson, L. M., Apro, A. C., Botticello-Romero, N. R., Bahr, C., Shin, M., Ward, K. M., Rosenberg, L., Ritov, V. B., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174675 · Cited by 205
Cheng, E., Whitsett, T. G., Tran, N. L., & Winkles, J. A. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0411 · Cited by 31
Bhagat, D. S., Chawla, P. A., Gurnule, W. B., Shejul, S. K., & Bumbrah, G. S. (2021) · Current Organic Chemistry · doi:10.2174/1385272825999210101234704 · Cited by 25
Kanemaru, R., Takahashi, F., Kato, M., Mitsuishi, Y., Tajima, K., Ihara, H., Hidayat, M., Wirawan, A., Koinuma, Y., Hayakawa, D., et al. (2018) · Lung · doi:10.1007/s00408-018-0134-6 · Cited by 26
Kumar, H., & Kim, P. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1789 · Cited by 29
Zhou, Q. S., Guo, X., & Choksi, R. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240507 · Cited by 24
Lee, D., Park, Y. H., Lee, J. E., Kim, H. S., Min, K. Y., Jo, M. G., Kim, H. S., Choi, W. S., & Kim, Y. M. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.013 · Cited by 22
Fuzo, C. A., Júnior, R. B. M., Fraga‐Silva, T. F. D. C., Amstalden, M. K., Léo, T. C. D., Souza, J. D. P., de Lima, T. M., Faccioli, L. H., Okamoto, D. N., Juliano, M. A., et al. (2022) · Drug Development Research · doi:10.1002/ddr.21982 · Cited by 22
Novel Treatment Approaches to Fibrosis in Scleroderma
Distler, J. H. W., & Distler, O. (2008) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2007.12.003 · Cited by 22
Signaling by the tyrosine kinase Yes promotes liver cancer development
Guégan, J., Lapouge, M., Voisin, L., Saba-El-Leil, M. K., Tanguay, P., Lévesque, K., Brégeon, J., Mes‐Masson, A., Lamarre, D., Haibe‐Kains, B., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abj4743 · Cited by 23
Marino, M., Cannarella, R., Condorelli, R. A., Crafa, A., Vignera, S. L., & Calogero, A. E. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102131 · Cited by 19
Selective antagonism of anticancer drugs for side-effect removal
Fernández, A., & Sessel, S. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.06.001 · Cited by 20
Targeting the unfolded protein response in head and neck and oral cavity cancers
Cole, D. W., Svider, P. F., Shenouda, K. G., Lee, P. B., Yoo, N. G., McLeod, T. M., Mutchnick, S. A., Yoo, G. H., Kaufman, R. J., Callaghan, M. U., et al. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.04.007 · Cited by 19
Chitre, T. S., Hirode, P. V., Lokwani, D. K., Bhatambrekar, A. L., Hajare, S. G., Thorat, S. B., Priya, D., Pradhan, K. B., Asgaonkar, K. D., & Jain, S. P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2262594 · Cited by 18
Improved Angiostatic Activity of Dasatinib by Modulation with Hydrophobic Chains
Păunescu, E., Clavel, C. M., Nowak-Sliwinska, P. M., Griffioen, A. W., & Dyson, P. J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500496u · Cited by 18
Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer
Wen, W. X., Han, E. S., Dellinger, T. H., Lu, L. X., Wu, J., Jove, R., & Yim, J. H. (2020) · Cancers · doi:10.3390/cancers12092586 · Cited by 17
Gurung, A. B., Ali, M. A., Elshikh, M. S., Aref, I., Amina, M., & Lee, J. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103297 · Cited by 18
Antibody drug conjugates beyond cytotoxic payloads
Hobson, A. D. (2023) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2023.10.001 · Cited by 17
Management of Bcr–Abl-positive leukemias with dasatinib
Hochhaus, A. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.11.1529 · Cited by 16
Min, H. K., Kim, S. H., Won, J., Kim, K., Lee, J., Lee, S., & Kim, H. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14627 · Cited by 15
El-Rashedy, A. A. E., Olotu, F. A., & Soliman, M. E. S. (2018) · Chemistry & Biodiversity · doi:10.1002/cbdv.201700533 · Cited by 15
Chapter 32 To Market, To Market – 2006
Hegde, S. G., & Schmidt, M. A. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42032-2 · Cited by 16
Proteome-Wide Deconvolution of Drug Targets and Binding Sites by Lysine Reactivity Profiling
Ruan, C., Zhou, J., Li, Z., Li, K., Fang, Z., Zhang, X., & Ye, M. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c05455 · Cited by 14
Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review
Mugiya, T., Mothibe, M. E., Khathi, A., Ngubane, P. S., & Sibiya, N. H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1355171 · Cited by 14
Chatzikalil, E., Stergiou, I. Ε., Papadakos, S. P., Konstantinidis, I., & Theocharis, S. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073834 · Cited by 14
Shinde, A., Panchal, K., Katke, S., Paliwal, R., & Chaurasiya, A. (2021) · Therapies · doi:10.1016/j.therap.2021.10.010 · Cited by 14
Cunningham, D. L., Creese, A. J., Auciello, G., Sweet, S. M. M., Tatar, T., Rappoport, J. Z., Grant, M. M., & Heath, J. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061513 · Cited by 14
Novel agents in ovarian cancer
Matei, D. E. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.8.1227 · Cited by 14
Hu, D., Du, J., Xing, Y., Cheng, Y., He, R., Liang, X., Li, H., & Yang, Y. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15714 · Cited by 13
Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
Magni, M., Biancon, G., Rizzitano, S., Cavanè, A., Paolizzi, C., Dugo, M., Corradini, P., & Carniti, C. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0557-8 · Cited by 13
Coates, M. S., Alton, E. W. F. W., Rapeport, G., Davies, J. C., & Ito, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246050 · Cited by 13
Sun, L., Yang, P., Li, L., Sun, J., & Wang, Y. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106678 · Cited by 11
Rizk, M. G., Magar, H. S., Fahim, A. M., & Mahmoud, N. H. (2024) · Applied Organometallic Chemistry · doi:10.1002/aoc.7343 · Cited by 11
Platelet-Derived Growth Factor Pathway Inhibitors in Ovarian Cancer
Schmitt, J., & Matei, D. E. (2008) · Clinical Ovarian Cancer · doi:10.3816/coc.2008.n.013 · Cited by 10
Obukohwo, O. M., Oghenetega, O. B., Faith, F. Y., Emojevwe, V. O., Rotu, R. A., Uchechukwu, J. G., & Abioye, O. A. (2023) · Asian Pacific Journal of Reproduction · doi:10.4103/2305-0500.377500 · Cited by 9
Andersen, G. T., Ianevski, A., Resell, M., Pojskić, N., Rabben, H.-L., Geithus, S., Kodama, Y., Tomita, H., Kainov, D. E., Grønbech, J. E., et al. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00455-0 · Cited by 9
Shooting the messenger: Targeting signal transduction pathways in leukemia and related disorders
Noor, S. M., Bell, R., & Ward, A. C. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.05.002 · Cited by 11
Cancer Therapies and Vascular Toxicities
Meilhac, A., Cautela, J., & Thuny, F. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00964-2 · Cited by 10
Crystal structure of the SH3 domain of human Lyn non-receptor tyrosine kinase
Berndt, S., Gurevich, V. V., & Iverson, T. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215140 · Cited by 9
Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib
Cassier, P. A., Dufresne, A., Arifi, S., Sayadi, H. E., Ray-Coquard, I. L., Bringuier, P., Scoazec, J., Alberti, L., & Blay, J. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0102-z · Cited by 9
Cui, J., Fu, R., Zhou, L., Chen, S., Li, G., Qian, S., & Liu, S. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.113 · Cited by 8
Structure-Selective Polydopamine Coating on Drug Nanoparticles
Niezni, D., Azagury, D. M., Avrashami, M., Bar-Natan, O., & Shamay, Y. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c19920 · Cited by 7
Metadata
- Authors
- Kantarjian, H., Jabbour, E., Grimley, J., & Kirkpatrick, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- IQVIA (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-09
- Volume
- 5
- Issue
- 9
- Pages
- 717-718
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4247947439
- Cited by
- 149
- References
- 11
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 19 · 2023: 11 · 2022: 14 · 2021: 13 · 2020: 5 · 2019: 6 · 2018: 3 · 2017: 3 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 5 · 2012: 6
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dasatinib, tyrosine kinase inhibitors, chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, imatinib resistance, drug approval, BCR-ABL
- MeSH terms
- Dasatinib, Administration, Oral, Adult, Clinical Trials as Topic, Humans, Pyrimidines, Thiazoles, Molecular Structure, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Treatment Outcome, Drug Approval, Guideline Adherence, Protein Kinase Inhibitors, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.